MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Adenosine antagonists"

  • 2018 International Congress

    Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease

    A. Pinna, G. Costa, M. Serra, M. Morelli (Monserrato (CA), Italy)

    Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…
  • 2018 International Congress

    The complementary relationship between zonisamide and istradefylline in treating patients with Parkinson’s disease

    T. Kadowaki, M. Hamaguchi, H. Sakuramoto, T. Shiina, H. Fujita, K. Suzuki, K. Hirata (Mibu, Japan)

    Objective: To investigate patients with Parkinson’s disease (PD) who received zonisamide and istradefylline at the same period. Background: Zonisamide and istradefylline are anti-PD drugs with…
  • 2017 International Congress

    Efficacy of Tozadenant in Animal Models of Non-Motor Symptoms of Parkinson’s Disease

    C. Kostrub, C. Kenney, C. Riemer, E. Prinssen, A. Flohr, J.-L. Moreau (Ardsley, NY, USA)

    Objective: Investigate the potential of tozadenant (TOZ) to alleviate the non-motor symptoms of Parkinson's disease using multiple animal models. Background: TOZ is an oral, selective…
  • 2017 International Congress

    Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease

    A. Verma, V. Kumar, U. Singh (Allahabad, India)

    Objective: In the present study, we intended to develop novel 1,2,4 triazole as potent A(2A)AR antagonists against parkinson’s disease. Background: Parkinson’s disease (PD) is a…
  • 2017 International Congress

    Istradefylline improves motor symptoms in Parkinson’s disease: A meta-analysis

    W. Sako, N. Murakami, K. Motohama, Y. Izumi, R. Kaji (Tokushima, Japan)

    Objective: The aim of this meta-analysis was to provide strong evidence for the main and side effects of istradefylline on patients with Parkinson’s disease. Background:…
  • 2017 International Congress

    Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.

    K. Ohta, Y. Kujuro, T. Osada (Tokyo, Japan)

    Objective:  This study analyzed the clinical effectiveness of istradefylline in terms of sleep disturbance in Parkinson’s disease (PD) patients. Background: A selective adenosine A2A receptor…
  • 2017 International Congress

    Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)

    R. Postuma, J. Anang, A. Pelletier, M. Moscovich, D. Grimes, A. Borys, S. Furtado, R. Munhoz, S. Cresswell, A. Moro, D. Hobson, L. Joseph, A. Lang (Montreal, QC, Canada)

    Objective: To assess the effects of caffeine on patients with Parkinson's disease. Background: Multiple studies have linked use of caffeine, an adenosine antagonist, to a…
  • 2017 International Congress

    Istradefylline and Preladenant as adjuvant therapies for Patients with Parkinson’s disease

    A. Negida, Z. Hassan, H. Ahmed, O. Hassan, A. Elsherbiny, S. Azzam, O. Osama, Y. Ibrahim (Zagazig, El-Sharkia, Egypt)

    Objective: The aim of this meta-analysis is to synthesize evidence about the efficacy of the adenosine receptor antagonists (Istradefylline and Preladenant) for patients with Parkinson’s…
  • 2016 International Congress

    Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson’s disease patients with motor fluctuations

    C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

    Objective: To analyze all dyskinesia data from a Phase 2b trial of fluctuating Parkinson patients in order to understand the overall impact a study drug…
  • 2016 International Congress

    Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations

    C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

    Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley